SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
180 hedge funds and large institutions have $2.77B invested in SpringWorks Therapeutics in 2023 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 78 increasing their positions, 34 reducing their positions, and 20 closing their positions.
330% more call options, than puts
Call options by funds: $29.4M | Put options by funds: $6.84M
165% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 20
129% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 34
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
75% more capital invested
Capital invested by funds: $1.58B → $2.77B (+$1.19B)
22% more funds holding
Funds holding: 147 → 180 (+33)
4.05% less ownership
Funds ownership: 109.42% → 105.37% (-4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$58.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$45.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$42.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$80M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$71.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$69.4M |
| 4 |
O
OrbiMed
New York
|
-$19.6M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.4M |
SWTX Hedge Fund Activity: Q4 2023 in Review
180 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2023, worth a combined $2.77B — up 75% from $1.58B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new SWTX positions and 20 closed out — a net gain of 33 holders — while 78 added to existing stakes and 34 trimmed.
The largest buyer was Maverick Capital, adding an estimated $58.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $80M sold.
- 180 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2023, up from 147 in Q3 2023.
- Funds reported $2.77B of SpringWorks Therapeutics stock for Q4 2023, up 75% quarter-over-quarter.
- 53 funds opened new SpringWorks Therapeutics positions in Q4 2023 and 20 closed out, a net change of +33 holders.
- The largest SpringWorks Therapeutics buyer in Q4 2023 was Maverick Capital, an estimated $58.3M added.
- The largest SpringWorks Therapeutics seller in Q4 2023 was EcoR1 Capital, an estimated $80M sold.
Based on aggregated 13F filings for Q4 2023.